CLINICAL TRIALS PROFILE FOR HEATHER

« Back to Dashboard

All Clinical Trials for HEATHER

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00209027 ↗	The Effects of Aripiprazole on the Processing of Rewards in Schizophrenia	Terminated	Bristol-Myers Squibb	N/A	2005-04-01	The objective of this study is to determine whether subjects with negative symptoms of schizophrenia have abnormal functioning of brain circuits relevant to reward processing, and to determine whether any such abnormalities are normalized by treatment with aripiprazole.
NCT00209027 ↗	The Effects of Aripiprazole on the Processing of Rewards in Schizophrenia	Terminated	Emory University	N/A	2005-04-01	The objective of this study is to determine whether subjects with negative symptoms of schizophrenia have abnormal functioning of brain circuits relevant to reward processing, and to determine whether any such abnormalities are normalized by treatment with aripiprazole.
NCT00854373 ↗	Concomitant Administration of FSH With HCG Improves Oocyte Maturation and Quality Double -Blinded Randomized Trial	Completed	University of California, San Francisco	Phase 4	2006-06-01	Marcelle Cedars, M.D., Victor Fujimoto, M.D., Mitch Rosen, M.D., Heather Huddleston, M.D., Paolo Rinaudo, M.D., Anthony Dobson, M.D., and Shehua Shen, M.D. from the UCSF Department of Obstetrics and Gynecology and Reproductive Sciences are conducting a study to learn about ovarian stimulation and oocyte maturation to improve fertilization, embryo quality, implantation and clinical pregnancy rates in patients undergoing in vitro fertilization (IVF). Two hormones, follicle stimulating hormone and human chorionic gonadotropin (FSH/hCG) will be compared to the standard one hormone, hCG, for the ovulation trigger. Over the past two decades, the success rate of assisted reproductive technology (ART) has dramatically increased. This increase has largely been attributed to improvements in the laboratory conditions and improvements in ovarian stimulation protocols (those medications used to increase the number of eggs maturing each cycle). Less work has been done on different ways to cause the final maturation of the eggs and the release of the egg from the ovary. The investigators propose to change the final injection prior to the egg retrieval (the ovulation trigger) so that it looks more like what happens in a normal menstrual cycle, where two hormones (both luteinizing hormone (LH) and FSH) increase. The investigators want to find out if this will improve egg quality and increase chances for pregnancy.

Clinical Trial Conditions for HEATHER

Condition Name

Condition Name for HEATHER
Intervention	Trials
Infertility	1
Schizophrenia	1

Condition MeSH

Condition MeSH for HEATHER
Intervention	Trials
Infertility	1
Schizophrenia	1

Clinical Trial Locations for HEATHER

Trials by Country

Trials by Country for HEATHER
Location	Trials
United States	2

Trials by US State

Trials by US State for HEATHER
Location	Trials
California	1
Georgia	1

Clinical Trial Progress for HEATHER

Clinical Trial Phase

Clinical Trial Phase for HEATHER
Clinical Trial Phase	Trials
Phase 4	1
N/A	1

Clinical Trial Status

Clinical Trial Status for HEATHER
Clinical Trial Phase	Trials
Completed	1
Terminated	1

Clinical Trial Sponsors for HEATHER

Sponsor Name

Sponsor Name for HEATHER
Sponsor	Trials
Bristol-Myers Squibb	1
Emory University	1
University of California, San Francisco	1

Sponsor Type

Sponsor Type for HEATHER
Sponsor	Trials
Other	2
Industry	1

Clinical Trials Update, Market Analysis, and Forecast for “HEATHER” Drug Candidate

Last updated: June 26, 2026

What is “HEATHER” in clinical development and who is sponsoring it?

No complete, verifiable identification of the “HEATHER” drug name (INN/brand/ALT code), active ingredient, developer, or development program can be produced from the provided input alone. Without the active ingredient and sponsor, clinical trial updates, endpoints, phase status, geography, and market sizing cannot be accurately mapped to regulatory filings, trial registries, or sales forecasts.

Which clinical trials are active for HEATHER and what are the latest readouts?

No complete, verifiable clinical-trial record for “HEATHER” can be tied to a specific molecule or sponsor from the provided input. A reliable update requires program identity to link to ClinicalTrials.gov, EU CTR, ISRCTN, Japan registries, or sponsor press releases.

What phases is HEATHER in (Phase 1, 2, 3), and what endpoints are being targeted?

Program identity is missing, so phase, inclusion criteria, comparators, primary endpoints, and safety signals cannot be correctly stated.

What trials are recruiting, enrolling by invitation, or completed for HEATHER?

Program identity is missing, so recruitment status, site counts, NCT/EudraCT numbers, and completion dates cannot be accurately listed.

What is the expected launch timeline for HEATHER based on clinical development and regulatory milestones?

No verifiable development program can be mapped to “HEATHER” from the provided input, so launch timing cannot be grounded in trial readouts, NDA/BLA submission planning, or FDA review timelines.

When will HEATHER be eligible for FDA approval, priority review, or accelerated approval?

Eligibility depends on mechanism, indication, trial design, and FDA communications tied to a specific product identity.

How long does the exclusivity runway look for HEATHER after approval?

Exclusivity starts from approval date for the specific NDA/BLA. Without product identity, exclusivity end dates (NCE, pediatric, patent term adjustments) cannot be stated.

What patents and exclusivity protect HEATHER and when do they expire?

Patent and exclusivity analysis cannot be produced without the active ingredient and specific product identifiers (NDA/BLA number, Orange Book/NPLID entries, patent list, assignee, and jurisdiction).

What is the competitive landscape for HEATHER by indication and mechanism of action?

A competitive landscape requires a defined indication, mechanism, and patient population. Those elements cannot be inferred from the provided input.

How does HEATHER compare with closest-in-class drugs and current standard of care?

Comparators and differentiation (efficacy, safety, administration, dosing, comorbidities) require program identity and clinical data.

What biosimilar or generic entry risks exist for HEATHER?

Entry risk depends on whether the product is small molecule, biologic, or gene/cell therapy, plus data protection and patent estate structure.

What is the market size for HEATHER and what are the revenue projections?

Market sizing depends on:

• indication and label scope
• efficacy and safety profile versus standard of care
• pricing assumptions and payer dynamics
• addressable patient population by geography
• competitive entry timing

None of these are available for “HEATHER” as provided.

What share assumptions drive the forecast for HEATHER (uptake curve, persistence, switching)?

Forecast mechanics require launch sequencing, expected prescribing behavior, and competitive products, which cannot be determined without product identity.

What sensitivity cases should be used for HEATHER (bull/base/bear) and why?

Sensitivity cases require clinical readout assumptions and regulatory probabilities tied to the specific development program.

How does pricing, reimbursement, and payer access likely affect HEATHER’s adoption?

Reimbursement analysis requires the indication, drug class, administration route, and expected clinical differentiation. Those inputs are not provided.

Key Takeaways

No actionable clinical-trial update, patent/exclusivity mapping, regulatory timeline, competitive assessment, or market projection can be produced from the single term “HEATHER” without a verifiable mapping to an active ingredient and sponsor-level development program.